Podcast
Vanguards of Healthcare by Bloomberg Intelligence
Hosted by Bloomberg · EN
Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.
11episodes
Episodes
Newest firstAll episodes
Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound
2d ago00:43:42Tap to summarize“It’s not just gonna be about image quality. It’s gonna be about image quality and interpretation”, Butterfly Network’s CEO Joe DeVivo explains to Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, DeVivo sits down with BI analyst Matt Henriksson for an in-depth interview to talk about Ultrasound-on-Chip imaging module and the potential of using semiconductor chips to streamline ultrasound as point-of-care option that allows immediate scans and diagnostics. They also discuss the development of Butterfly’s Apollo, a machine designed to be 20x more powerful than its current iQ3 that will create images closer to how the anatomy looks and power its recently announced partnership with Midjourney for a full-body tomographic-imaging machine that utilizes Butterfly’s Ultrasound-on-Chip imaging modules.See omnystudio.com/listener for privacy information.
Transcribe →Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket
1w ago00:50:47Tap to summarize“The number one thing that results in a better outcome for someone who is sick is actually, ‘Do you have an advocate on your side?’” says Farid Vij, co-founder and CEO of Citizen Health. Vij joins Bloomberg Intelligence analyst Jonathan Palmer to explain how Citizen Health is building an AI-powered advocate for patients with rare and complex diseases. He discusses the company’s mission to aggregate longitudinal health data, support caregivers, accelerate research and create a future where personalized guidance replaces one-size-fits-all medicine.See omnystudio.com/listener for privacy information.
Transcribe →Distalmotion’s Approach to Spread Surgical Robots to More
2w ago00:36:38Tap to summarize“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.See omnystudio.com/listener for privacy information.
Transcribe →Bristol Myers on Why Neuroscience Could Be the Next Oncology
3w ago01:03:48Tap to summarize“Neuroscience is what oncology was 20 years ago,” says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers’ push into neuroscience, including Alzheimer’s therapies aimed at tau, a protein tied to brain tangles in the disease. They also explore the company’s oncology pipeline, including PD-L1/VEGF bispecifics, next-generation antibody-drug conjugates and advances in multiple myeloma. Massacesi explains how Bristol is balancing internal innovation with external partnerships and why AI could fundamentally change the economics and success rates of drug development.See omnystudio.com/listener for privacy information.
Transcribe →Restor3D Combines AI with 3D Printing to Create Personalized Ortho Solutions
3w ago00:40:30Tap to summarize“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room. The in-depth interview covered restor3D’s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies. Listen to this episode on Apple Podcasts and Spotify. See omnystudio.com/listener for privacy information.
Transcribe →AstraZeneca’s ASCO Readout on Oncology’s Next Wave
4w ago00:57:59Tap to summarize“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.See omnystudio.com/listener for privacy information.
Transcribe →Ocular Therapeutix Cuts Blindness Toll
May 2800:23:50Tap to summarize“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the mortality doesn’t change, the use of resources skyrockets, but the mortality doesn’t change. In this country, every blind patient costs over $66,000 a year,” says Pravin Dugel, CEO of Ocular Therapeutix. “If we reduce that dropout rate by even 10% with Axpaxli, and I’m sure we’ll do even better, we’re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.” In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.See omnystudio.com/listener for privacy information.
Transcribe →IRhythm Pushes a Proactive Approach to Monitoring
May 2100:46:11Tap to summarize“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals. Listen to this episode on Apple Podcasts and Spotify.See omnystudio.com/listener for privacy information.
Transcribe →Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA
May 1400:45:17Tap to summarizeBased on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.See omnystudio.com/listener for privacy information.
Transcribe →RTW’s Rod Wong on Biotech’s Revival and the Global Shift
May 700:49:52Tap to summarize“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech’s rebound, why fundamentals may finally be improving after a prolonged bear market and how China’s speed and cost advantages are reshaping global drug discovery. They also explore AI’s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.See omnystudio.com/listener for privacy information.
Transcribe →